GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Landos Biopharma Inc (NAS:LABP) » Definitions » Cash Flow from Investing

Landos Biopharma (Landos Biopharma) Cash Flow from Investing : $4.67 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Landos Biopharma Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Landos Biopharma spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Landos Biopharma gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Landos Biopharma Cash Flow from Investing Historical Data

The historical data trend for Landos Biopharma's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Landos Biopharma Cash Flow from Investing Chart

Landos Biopharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial -40.33 14.13 -58.71 74.06 7.78

Landos Biopharma Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.10 3.97 0.63 0.06 -

Landos Biopharma Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Landos Biopharma's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Landos Biopharma's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Landos Biopharma  (NAS:LABP) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Landos Biopharma's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Landos Biopharma spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Landos Biopharma's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Landos Biopharma gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Landos Biopharma's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Landos Biopharma spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Landos Biopharma's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Landos Biopharma gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Landos Biopharma's purchase of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Landos Biopharma spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Landos Biopharma's sale of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Landos Biopharma gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Landos Biopharma's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Landos Biopharma paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Landos Biopharma's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Landos Biopharma paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Landos Biopharma's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Landos Biopharma paid $0.00 Mil for other investing activities.


Landos Biopharma Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Landos Biopharma's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Landos Biopharma (Landos Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 11239, Blacksburg, VA, USA, 24060
Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. It operates in one reportable segment of operations and manages.
Executives
Alka Batycky director C/O LANDOS BIOPHARMA, INC., P.O. BOX 11239, BLACKSBURG VA 24062
Perceptive Xontogeny Venture Fund Ii, Lp 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Roderick Wong 10 percent owner C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fabio Cataldi officer: Chief Medical Officer C/O LANDOS BIOPHARMA, INC., PO BOX 11239, BLACKSBURG VA 24062
Gregory Oakes director, officer: Chief Executive Officer 760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226
Patrick Truesdell officer: Vice President and Controller C/O LANDOS BIOPHARMA, INC., 1800 KRAFT DRIVE, SUITE 216, BLACKBURG VA 24060
Roger Adsett director 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Josep Bassaganya-riera director, 10 percent owner, officer: Chairman, President and CEO 1800 KRAFT DRIVE, SUITE 100, BLACKSBURG VA 24060
Patricia L Bitar officer: Interim CFO C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, STE 700, SAN DIEGO CA 92122
Perceptive Xontogeny Venture Fund, Lp director C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Xontogeny, Llc director 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Fred Callori director 100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110
Joseph Edelman director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003

Landos Biopharma (Landos Biopharma) Headlines